DK2464356T3 - Sigma-ligander til forebyggelse eller behandling af smerte induceret af kemoterapi - Google Patents
Sigma-ligander til forebyggelse eller behandling af smerte induceret af kemoterapi Download PDFInfo
- Publication number
- DK2464356T3 DK2464356T3 DK10744560.3T DK10744560T DK2464356T3 DK 2464356 T3 DK2464356 T3 DK 2464356T3 DK 10744560 T DK10744560 T DK 10744560T DK 2464356 T3 DK2464356 T3 DK 2464356T3
- Authority
- DK
- Denmark
- Prior art keywords
- unsubstituted
- substituted
- paclitaxel
- compound
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Kombination af mindst én sigma-ligand og mindst ét kemoterapeutisk lægemiddel til samtidig, separat eller sekventiel administration, hvor sigma-liganden harden almene formel (I):
(i) hvor Ri er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret aryl-alkyl, substitueret eller usubstitueret ikke-aromatisk heterocyclyl, substitueret eller usubstitueret aromatisk heterocyclyl, substitueret eller usubstitueret hetero-cyclylalkyl, -COR8, -C(0)0R8, -C(0)NR8R9, -CH=NR8, -CN, -OR8, -0C(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -NO2, -N=CR8R9 og halogen; R2 er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret aryl-alkyl, substitueret eller usubstitueret, aromatisk eller ikke-aromatisk heterocyclyl, substitueret eller usubstitueret heterocyclylalkyl, -COR8, -C(0)0R8, -C(0)NR8R9, -CH=NR8, -CN, -OR8, -0C(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -NO2, -N=CR8R9 og halogen; R3 og R4 uafhængigt er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret arylalkyl, substitueret eller usubstitueret, aromatisk eller ikke-aro- matisk heterocyclyl, substitueret eller usubstitueret heterocyclylalkyl, -COR8, -C(0)0R8, -C(0)NR8R9, -CH=NR8, -CN, -OR* -0C(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9j -NO2, -N=CR8R9 og halogen, eller tilsammen danner de et eventuelt substitueret fusioneret ringsystem; R5 og R6 uafhængigt er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret arylalkyl, substitueret eller usubstitueret, aromatisk eller ikke-aro-matisk heterocyclyl, substitueret eller usubstitueret heterocyclylalkyl, -COR8, -C(0)0R8, -C(0)NR8R9, -CH=NR8, -CN, -OR8, -0C(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -NO2, -N=CR8R9 og halogen eller danner sammen med det nitrogenatom, til hvilket de er bundet, en substitueret eller usubstitueret heterocyclyl-gruppe; n er valgt blandt 1,2,3, 4, 5, 6, 7 og 8; t er 1,2 eller 3; R8 og Rg hver især uafhængigt er valgt blandt hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret, aromatisk eller ikke-aromatisk heterocyclyl, substitueret eller usubstitueret alkoxy, substitueret eller usubstitueret aryloxy og halogen; eller et farmaceutisk acceptabelt salt, isomer eller solvat deraf; og det kemoterapeutiske lægemiddel er valgt fra gruppen bestående af taxaner, vinca-alkaloider, lægemidler afledt fra platin og thalidomid.
2. Kombination ifølge krav 1, hvor R-ι er valgt blandt H, -COR8 og substitueret eller usubstitueret alkyl.
3. Kombination ifølge krav 1 eller 2, hvor R2 er H eller alkyl.
4. Kombination ifølge et hvilket som helst af de foregående krav, hvor R3 og R4 tilsammen danner et fusioneret naphthylringsystem.
5. Kombination ifølge et hvilket som helst af de foregående krav, hvor R5 og R6 tilsammen danner en morpholin-4-yl-gruppe.
6. Kombination ifølge et hvilket som helst af de foregående krav, hvor sigma-liganden med formel (I) er 4-{2-[5-methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}morpholin eller et farmaceutisk acceptabelt salt, isomer eller solvat deraf.
7. Kombination ifølge et hvilket som helst af de foregående krav, hvor sigma-liganden med formel (I) er 4-{2-[5-methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}morpholin-hydrochlorid.
8. Kombination ifølge et hvilket som helst af de foregående krav, hvor det kemotera-peutiske lægemiddel er valgt fra gruppen bestående af paclitaxel, oxaliplatin, cisplatin, vineristin og thalidomid.
9. Kombination ifølge et hvilket som helst af de foregående krav, hvor kombinationen omfatter 4- {2-[5-methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}morpholin og et kemoterapeutisk lægemiddel, som er valgt blandt paclitaxel, oxaliplatin eller cisplatin.
10. Kombination som defineret i et hvilket som helst af kravene 1 til 9 til anvendelse til fremstilling af et lægemiddel.
11. Kombination som defineret i et hvilket som helst af kravene 1 til 9 til anvendelse til forebyggelse eller behandling af smerte, som er induceret af kemoterapi.
12. Kombination ifølge krav 11, hvor smerten er valgt blandt perifer neuropatisk smerte, allodyni, causalgi, hyperalgesi, hyperæstesi, hyperpati, neuralgi, neuritis og neuropati.
13. Forbindelse med formel (I) som defineret i et hvilket som helst af kravene 1 til 7 eller et farmaceutisk acceptabelt salt, isomer eller solvat deraf til anvendelse til behandling eller forebyggelse af smerte, som er induceret af kemoterapi, hvor det kemo-terapeutiske lægemiddel er valgt fra gruppen bestående af taxaner, vinca-alkaloider, lægemidler afledt fra platin og thalidomid.
14. Forbindelse ifølge krav 13 eller et farmaceutisk acceptabelt salt, isomer eller solvat deraf til anvendelse til forebyggelse af smerte, som er induceret af kemoterapi, hvor det kemoterapeutiske lægemiddel er valgt fra gruppen bestående af taxaner, vinca-alkalo-ider, lægemidler afledt fra platin og thalidomid.
15. Forbindelse ifølge krav 13 eller 14, hvor smerten er valgt blandt perifer neuropatisk smerte, allodyni, causalgi, hyperalgesi, hyperæstesi, hyperpati, neuralgi, neuritis og neuropati.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382144A EP2292236A1 (en) | 2009-08-14 | 2009-08-14 | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| PCT/EP2010/061720 WO2011018487A1 (en) | 2009-08-14 | 2010-08-12 | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2464356T3 true DK2464356T3 (da) | 2015-07-13 |
Family
ID=41531868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10744560.3T DK2464356T3 (da) | 2009-08-14 | 2010-08-12 | Sigma-ligander til forebyggelse eller behandling af smerte induceret af kemoterapi |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20120141606A1 (da) |
| EP (2) | EP2292236A1 (da) |
| JP (1) | JP5922575B2 (da) |
| KR (3) | KR101605151B1 (da) |
| CN (1) | CN102497864B (da) |
| AR (1) | AR077876A1 (da) |
| AU (2) | AU2010283761B2 (da) |
| BR (1) | BR112012003053A2 (da) |
| CA (1) | CA2770441C (da) |
| CO (1) | CO6511240A2 (da) |
| CY (1) | CY1116697T1 (da) |
| DK (1) | DK2464356T3 (da) |
| EC (1) | ECSP12011658A (da) |
| ES (1) | ES2543645T3 (da) |
| HK (1) | HK1171945A1 (da) |
| HR (1) | HRP20150788T1 (da) |
| HU (1) | HUE025642T2 (da) |
| IL (1) | IL217911A0 (da) |
| IN (1) | IN2012DN02149A (da) |
| MA (1) | MA33569B1 (da) |
| MX (1) | MX2012001877A (da) |
| MY (1) | MY157334A (da) |
| NZ (1) | NZ598213A (da) |
| PL (1) | PL2464356T3 (da) |
| PT (1) | PT2464356E (da) |
| RU (1) | RU2543382C2 (da) |
| SG (1) | SG178338A1 (da) |
| SI (1) | SI2464356T1 (da) |
| SM (1) | SMT201500189T1 (da) |
| TN (1) | TN2012000048A1 (da) |
| TW (1) | TWI529168B (da) |
| UA (1) | UA108859C2 (da) |
| WO (1) | WO2011018487A1 (da) |
| ZA (1) | ZA201200843B (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2388005A1 (en) * | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| AR100021A1 (es) * | 2013-09-12 | 2016-09-07 | Esteve Labor Dr | Combinaciones de ligando de receptores sigma y aine |
| KR20160097366A (ko) | 2013-12-17 | 2016-08-17 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 세로토닌-노르에피네프린 재흡수 억제제들(SNRIs) 및 시그마 리셉터 리간드들 조합 |
| TN2016000229A1 (en) | 2013-12-17 | 2017-10-06 | Esteve Labor Dr | Gabapentinoids and sigma receptor ligands combinations. |
| AR108682A1 (es) * | 2016-06-06 | 2018-09-12 | Esteve Labor Dr | Derivados de pirazol-3-iloxi ligandos del receptor sigma |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
| WO2024105225A1 (en) * | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
| FR2301250A1 (fr) * | 1975-02-21 | 1976-09-17 | Bellon Labor Sa Roger | Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels |
| EP1634872A1 (en) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| ES2396421T3 (es) * | 2004-08-27 | 2013-02-21 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma |
| BRPI0514692A (pt) | 2004-08-27 | 2008-06-17 | Esteve Labor Dr | inibidores do receptor sigma |
| WO2007098953A1 (en) * | 2006-03-01 | 2007-09-07 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| CN101395157A (zh) * | 2006-03-01 | 2009-03-25 | 伊斯特芬博士实验室有限公司 | 作为西格玛受体抑制剂的吡唑衍生物 |
-
2009
- 2009-08-14 EP EP09382144A patent/EP2292236A1/en not_active Withdrawn
-
2010
- 2010-08-10 TW TW099126632A patent/TWI529168B/zh not_active IP Right Cessation
- 2010-08-12 IN IN2149DEN2012 patent/IN2012DN02149A/en unknown
- 2010-08-12 PL PL10744560T patent/PL2464356T3/pl unknown
- 2010-08-12 KR KR1020127006715A patent/KR101605151B1/ko not_active IP Right Cessation
- 2010-08-12 ES ES10744560.3T patent/ES2543645T3/es active Active
- 2010-08-12 NZ NZ598213A patent/NZ598213A/en not_active IP Right Cessation
- 2010-08-12 CN CN201080036098.6A patent/CN102497864B/zh active Active
- 2010-08-12 US US13/389,733 patent/US20120141606A1/en not_active Abandoned
- 2010-08-12 DK DK10744560.3T patent/DK2464356T3/da active
- 2010-08-12 PT PT107445603T patent/PT2464356E/pt unknown
- 2010-08-12 WO PCT/EP2010/061720 patent/WO2011018487A1/en active Application Filing
- 2010-08-12 KR KR1020177028558A patent/KR20170125951A/ko not_active Application Discontinuation
- 2010-08-12 AU AU2010283761A patent/AU2010283761B2/en not_active Ceased
- 2010-08-12 KR KR1020157034281A patent/KR20150140419A/ko active Search and Examination
- 2010-08-12 CA CA2770441A patent/CA2770441C/en not_active Expired - Fee Related
- 2010-08-12 JP JP2012524233A patent/JP5922575B2/ja active Active
- 2010-08-12 MY MYPI2012000561A patent/MY157334A/en unknown
- 2010-08-12 BR BR112012003053A patent/BR112012003053A2/pt not_active IP Right Cessation
- 2010-08-12 SG SG2012009098A patent/SG178338A1/en unknown
- 2010-08-12 RU RU2012109554/04A patent/RU2543382C2/ru not_active IP Right Cessation
- 2010-08-12 SI SI201030977T patent/SI2464356T1/sl unknown
- 2010-08-12 MX MX2012001877A patent/MX2012001877A/es active IP Right Grant
- 2010-08-12 EP EP10744560.3A patent/EP2464356B1/en active Active
- 2010-08-12 HU HUE10744560A patent/HUE025642T2/en unknown
- 2010-08-13 AR ARP100102983A patent/AR077876A1/es unknown
- 2010-12-08 UA UAA201202969A patent/UA108859C2/ru unknown
-
2012
- 2012-01-31 TN TNP2012000048A patent/TN2012000048A1/en unknown
- 2012-02-02 IL IL217911A patent/IL217911A0/en unknown
- 2012-02-03 ZA ZA2012/00843A patent/ZA201200843B/en unknown
- 2012-02-09 EC ECSP12011658 patent/ECSP12011658A/es unknown
- 2012-03-08 MA MA34669A patent/MA33569B1/fr unknown
- 2012-03-14 CO CO12044528A patent/CO6511240A2/es not_active Application Discontinuation
- 2012-12-10 HK HK12112740.4A patent/HK1171945A1/xx not_active IP Right Cessation
-
2015
- 2015-07-15 CY CY20151100618T patent/CY1116697T1/el unknown
- 2015-07-16 HR HRP20150788TT patent/HRP20150788T1/hr unknown
- 2015-08-05 SM SM201500189T patent/SMT201500189T1/xx unknown
-
2016
- 2016-03-17 US US15/073,460 patent/US20160199380A1/en not_active Abandoned
- 2016-04-07 US US15/093,589 patent/US20160220575A1/en not_active Abandoned
- 2016-09-14 AU AU2016228207A patent/AU2016228207B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016228207B2 (en) | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | |
| TWI510484B (zh) | 用於預防及／或治療因化學治療或放射治療所引起之嘔吐的σ配子 | |
| DK2254579T3 (da) | Anvendelse af forbindelser, der binder til sigmareceptor-liganderne, til behandling af neuropatisk smerte, der udvikles som følge af kemoterapi | |
| ES2388253B1 (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia |